Skip Navigation

Technology Transfer and Intellectual Property

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Recent Happenings

 

Click the text below to find or hide additional information.

Open All

Inventors Recognition Program

In the first half of FY 2014, NIAID recognized the following individuals for their contributions to the U.S. patents listed below (only current NIAID employees are shown):

 

Recent Patents

United States patent US 8,568,739 was issued on Oct. 29, 2013, for Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses. NIAID inventor: Alexander Pletnev, Ph.D., D.Sci.

United States patent US 8,580,277 was issued on Nov. 12, 2013, for Influenza hemagglutinin and neuraminidase variants. NIAID inventor: Kanta Subbarao, M.B.B.S., M.P.H.

United States patent US 8,629,260 was issued on Jan. 14, 2014, for Anti-arthropod vector vaccines, methods of selecting, and uses thereof. NIAID inventors: Jesus Valenzuela, Ph.D.; Yasmine Belkaid , Ph.D.; Shaden Kamhawi, Ph.D.; David Sacks, Ph.D.; Jose Ribeiro, M.D., Ph.D.

United States patent US 8,574,853 was issued on Nov. 5, 2013, for Monoclonal antibodies that neutralize anthrax toxins. NIAID inventors: Stephen Leppla, Ph.D., Suzanne Emerson, Ph.D. (retired)

United States patent US 8,623,371 was issued on Jan. 7, 2014, for Targeting poly-gama-glutamic acid to treat Staphylococcus epidermidis and related infections. NIAID inventor: Michael Otto, Ph.D.

United States patent US 8,628,780 was issued on Jan. 14, 2014, for Lutzomyia longipalpis polypeptides and methods of use. NIAID inventors: Jesus Valenzuela, Ph.D.; Jose Ribeiro, M.D., Ph.D.

 

Recent Collaborative Agreements

NIAID and GeoVax, Inc., signed a cooperative research and development agreement (CRADA) to develop new modified vaccinia ankara (MVA) vaccine vectors for HIV vaccines. NIAID principal investigator: Bernie Moss, M.D., Ph.D.

NIAID and Amgen, Inc., signed a CRADA to understand the immune response to chronic viral infection using IL-36 knock-out mice. NIAID principal investigator: Ethan M. Shevach, M.D.

NIAID and California Institute for Biomedical Research signed a CRADA to identify small molecule inhibitors of magnesium transporter protein 1 (MagT1) as lead pharmaceutical compounds. NIAID principal investigator: Michael J. Lenardo, M.D.

NIAID and the Infectious Disease Research Institute (IDRI) signed a CRADA to assess the efficacy of leishmania vaccines against vector-transmitted visceral leishmaniasis. NIAID principal investigator: Jesus G. Valenzuela, Ph.D.

NIAID and Protein Potential, LLC, entered into a research collaboration agreement (RCA) to collaboratively produce one or more conjugates of Protein Potential’s PvCSP (Protein 3 or P3) and evaluate its potential as a malaria vaccine that would act by inhibiting liver stage developmentof the Plasmodium vivax parasite. NIAID principal investigator: Patrick E. Duffy, M.D.

NIAID and Sanofi Pasteur Inc. signed a CRADA to conduct a Phase I study of the safety of Sanofi Pasteur's proprietary herpes simplex virus (HSV-2) vaccine containing deletions in the HSV-2 UL5 and UL29 genes (dl5-29) in adults with and without herpes simplex virus infection. NIAID principal investigator: Jeffrey Cohen, M.D.  

NIAID and University of Cambridge entered into an RCA to develop novel affinity ligands for assays and the purification of alphaviruses and influenza ferritin nanoparticle vaccines. NIAID principal investigator: Richard Schwartz, Ph.D.

NIAID, Merck Sharp & Dohme Corp., and St. Michael's Hospital signed a CRADA to study the identification of the source of persistent HIV plasma viremia in HIV-infected individuals and examination of the effect of the therapy intensification, by adding Merck's Raltegravir, on residual plasma viremia in infected individuals receiving effective antiretroviral therapy. NIAID principal investigator: Ulrich Siebenlist, Ph.D.; Tae-Wook Chun, Ph.D.  

NIAID and Gilead Sciences, Inc., signed a CRADA to study the safety and efficacy of Gilead's proprietary compounds including GS7977, GS5885, and GS9669 to treat hepatitis C/HIV coinfection and HCV infection in hard-to-treat populations and identification of the clinical and biological correlates associated with treatment response. NIAID principal investigator: Shyamasundaran Kottilil M.D., Ph.D.

NIAID and the University of New Mexico Health Sciences Center entered into an RCA to study the development of virus-like particles for use as immunogens to induce broadly neutralizing HIV and influenza responses. NIAID principal investigator: John Mascola, M.D.

NIAID and Amgen, Inc., signed a CRADA to study the use of Amgen's proprietary anti-IL-36 receptor and anti-IL-36 monoclonal antibodies to study the mechanisms of imiquimod-induced inflammatory responses and hapten exposure-induced contact hypersensitivity reactions in mouse skin. NIAID principal investigator: Ulrich Siebenlist, Ph.D.  

NIAID and GlobeImmune, Inc., entered into an RCA to study the effect of CD8+ and CD4+ T cells stimulated with GlobeImmune's proprietary Tarmogen products on the level of HIV replication and persistent viral reservoirs in HIV-infected individuals receiving antiretroviral therapy. NIAID principal investigator: Tae-Wook Chun, Ph.D.

NIAID and Impact Biologicals Inc. signed an RCA to test rPrions in RT Quic Assay. NIAID principal investigator: Byron Caughey, Ph.D.

NIAID and Philips Healthcare signed an RCA to study imaging of biosafety level four (BSL-4) disease processes. NIAID principal investigator: Peter Jahrling, Ph.D.

NIAID and Purdue University signed an RCA to study novel approaches to vaccine development: using chimeric alphavirus virus-like particles (VLPs). NIAID principal investigators: John Mascola, M.D.

NIAID, NIH Center for Regenerative Medicine, and Sangamo BioSciences, Inc., entered into an RCA to develop novel treatments for chronic granulomatous disease. NIAID principal investigator: Harry L. Malech, M.D.

NIAID and GlaxoSmithKline (GSK) signed a CRADA for the use of GSK’s proprietary GSK1210151A to study and intervene in aberrant inflammatory responses associated with Immune Reconstitution Syndrome (IRIS.) NIAID principal investigator: Philip M. Murphy, M.D.

NIAID and the University of North Carolina at Chapel Hill entered into an RCA to analyze progeny from a genetic cross of Plasmodium vivax parasites that differ in their responses to chloroquine. NIAID principal investigator: Thomas Wellems, M.D., Ph.D.

NIAID and Fibrogen, Inc., signed a CRADA to study hypoxia and the effects on helper T-cell differentiation using Fibrogen's proprietary hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitor FG-4497. NIAID principal investigator: Stefan Muljo, Ph.D.  

NIAID and Vedantra Pharmaceuticals signed an RCA to improve the immunogenicity of transmission-blocking vaccine antigens developed at the Laboratory of Malaria Immunology and Vaccinology by incorporating Pfs25 into the nanotechnology vaccine platform developed at Vedantra and assessing it in animal experiments. NIAID principal investigator: Patrick Duffy, M.D.

NIAID and Wistar Institute of Anatomy and Biology entered into an RCA to use influenza HA probes developed at the VRC to identify influenza-specific B-cell responses. NIAID principal investigator: John Mascola, M.D.

NIAID and Amgen, Inc., signed a CRADA to study the enhancement of donor bone marrow cell engraftment by osteoclast depletion. NIAID principal investigator: Philip M. Murphy, M.D.  

NIAID and GlaxoSmithKline Biologicals SA (GSK) entered into a CRADA to study a vaccine strategy to interrupt malaria transmission- investigator suitability of GSK's proprietary adjuvant systems for formulations of Pfs25 conjugates. NIAID principal investigator: Patrick Duffy, M.D.

NIAID and the Infectious Disease Research Institute (IDRI) entered into an RCA to study leishmania vaccine candidates in a model of natural transmission of leishmania by using colonized infected sand flies. NIAID principal investigator: Jesus Valenzuela, Ph.D.

NIAID and GlaxoSmithKline (GSK) signed a CRADA to evaluate the protective effects of GSK proprietary compound CRX-601, a lipid-A mimetic Toll-like receptor 4 agonist, in acute severe respiratory virus infection. NIAID principal investigator: Helene F. Rosenberg, M.D., Ph.D..

NIAID and the University of Texas at Austin entered into an RCA to identify antibody sequences from NIAID human B cells isolated from vaccinees exposed to viral pathogens. NIAID principal investigator: Daniel Douek, M.D., Ph.D.; Mark Connors, M.D.  

NIAID and TNI BioTech, Inc., signed a CRADA to study the mechanism of action and the therapeutic efficacy of the pan-opioid receptor inhibitor naltrexone and the u-opioid receptor agonists, [D-Arg2,Lys4]dermorphin-(1,4) -amide (DALDA) and [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO), in mice with oxazolone colitis. NIAID principal investigator: Warren Strober, M.D.

NIAID and Walter Reed National Military Medical Center (WRNMMC) entered into an RCA to conduct a study of rifaximin with a case cross-over design in virologically suppressed HIV-infected persons receiving ART. NIAID principal investigators: Daniel Douek, M.D., Ph.D.

NIAID and Codagenix Inc. signed an RCA to conduct additional studies in ferrets, an animal model for the study of influenza, to ascertain the optimal dose that is immunogenic and protects ferrets against challenge but is adequately attenuated. NIAID principal investigator: Kanta Subbarao, M.B.B.S., M.P.H.

NIAID and Montana State University signed an RCA to develop respiratory syncytial virus (RSV) vaccines using Phage capsid technology. NIAID principal investigator: Barney Graham, M.D., Ph.D.

NIAID, National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and Merck Sharp & Dohme Corp. signed a CRADA to study the effects of Merck Sharp & Dohme Corp.'s proprietary anti-IL-17A (JL7.1D10) and/or anti-IL-23R (21A4) monoclonal antibodies in murine models of skin inflammation. NIAID principal investigator: Ulrich Siebenlist, Ph.D..

NIAID and Novo Nordisk A/S signed a CRADA to study the effect of X38, a hormonally inactive insulin analogue proprietary to Novo Nordisk A/S, on deleting antigen-specific T cells and preventing glucose intolerance. NIAID principal investigator: Michael Lenardo, M.D.  

NIAID and GlaxoSmithKline LLC (GSK) signed a CRADA to study probiotic therapy: development of probiotics for the prevention of respiratory infections. NIAID principal investigator: Helene F. Rosenberg, M.D., Ph.D..

Last Updated April 02, 2014